Compositions comprising bacterial strains
The invention provides compositions comprising bacterial strains for treating and preventing inflammatory and autoimmune diseases.
1. A pharmaceutical composition that comprises:
from about 1×10 3 to about 1×10 11 colony forming units (CFU)/g of a single therapeutically active bacterial strain, with respect to a total weight of said pharmaceutical composition, wherein said single therapeutically active bacterial strain is a bacterial strain of the species Erysipelatoclostridium ramosum , wherein the single therapeutically active bacterial strain is a spore-forming bacterial strain, and wherein said single therapeutically active bacterial strain is lyophilized; and
a pharmaceutically acceptable excipient, diluent, or carrier.
2. The pharmaceutical composition of claim 1 , wherein said pharmaceutically acceptable excipient, diluent, or carrier comprises a lyoprotectant.
3. The pharmaceutical composition of claim 1 , wherein said pharmaceutical composition comprises from about 1×10 6 to about 1×10 11 colony forming units (CFU)/g of said single therapeutically active bacteria strain with respect to said total weight of said pharmaceutical composition.
4. The pharmaceutical composition of claim 1 , wherein said pharmaceutical composition is an oral formulation.
5. The pharmaceutical composition of claim 4 , wherein said pharmaceutical composition is a solid pharmaceutical composition.
6. The pharmaceutical composition of claim 1 , wherein said pharmaceutical composition is in the form of a tablet or a capsule.
7. The pharmaceutical composition of claim 1 , wherein said pharmaceutical composition is an enteric formulation.
8. The pharmaceutical composition of claim 1 , wherein said pharmaceutical composition further comprises a prebiotic compound selected from the group consisting of: a fructo-oligosaccharide, a short-chain fructo-oligosaccharide, inulin, an isomalt-oligosaccharide, a transgalacto-oligosaccharide, a pectin, a xylo-oligosaccharide, a chitosan-oligosaccharide, a beta-glucan, and arable gum modified starch, a polydextrose, a D-tagatose, an acacia fiber, a carob, an oat, and a citrus fiber.
9. The pharmaceutical composition of claim 1 , wherein at least 50% of said single therapeutically active bacteria strain as measured by an amount of colony forming units (CFU) remains viable after about 1 year of storage when said pharmaceutical composition is stored in a closed container at 25° C. at 95% relative humidity.
10. A method of treating inflammation characterized by an elevated level of an IL-17 cytokine in a subject in need thereof, comprising administering to said subject a pharmaceutical composition that comprises: a therapeutically effective amount of a therapeutically active bacterial strain, wherein said therapeutically effective bacterial strain is a bacterial strain of the species Erysipelatoclostridium ramosum , and a pharmaceutically acceptable excipient, diluent, or carrier,
wherein said therapeutically active bacterial strain is a spore-forming bacterial strain, wherein said therapeutically active bacterial strain is lyophilized; and
wherein said administering is sufficient to reduce said elevated level of said IL-17 cytokine relative to a level of said IL-17 cytokine prior to said administering, thereby treating said inflammation.
11. The method of claim 10 , wherein said inflammation is associated with uveitis, and wherein said treating comprises reducing retinal damage in uveitis.
12. The method of claim 10 , further comprising administering an additional therapeutic agent to said subject.
13. The method of claim 10 , wherein said pharmaceutical composition comprises from about 1×10 3 to about 1×10 11 colony forming units (CFU)/g of said therapeutically active bacteria strain with respect to a total weight of said pharmaceutical composition.
14. The method of claim 10 , wherein said administering is oral.
15. The method of claim 10 , wherein said pharmaceutical composition is a solid pharmaceutical composition.
16. The method of claim 10 , wherein said pharmaceutical composition is in the form of a tablet or a capsule.
17. The method of claim 10 , wherein said pharmaceutical composition is an enteric formulation.